You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. 2-HOBA for Treatment of Pulmonary Hypertension

    SBC: MTI Biotech Incorporated            Topic: NHLBI

    PROJECT SUMMARY Although the ubiquity of metabolic problems in pulmonary hypertension (PH) has been known for more than a decade, a wealth of new details on the nature of this problem presents the opportunity for intervention. A combination of experimental work in cells and animals and early trials in humans, suggests that these metabolic problems are part of the causation for PH, and that inactiv ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. An Improved Epigenetic Algorithm for Guiding Low Dose CT Lung Cancer Screening

    SBC: BEHAVIORAL DIAGNOSTICS, INC.            Topic: NCI

    SPECIFIC AIMSApproximately 90% of lung cancer results from smoking. Low Dose Computerized Tomography (LDCT) of smokers can detect lung cancer earlier allowing more effective treatment. But determining which smokers should get LDCT screening is controversial and potentially harmful. Recently, the U.S Preventive Services Task Force (USPSTF) updated their opinion on screening to recommend annual LDCT ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies

    SBC: EXAVIR THERAPEUTICS INC.            Topic: NIAID

    PROJECT SUMMARY While there are now successful treatment regimens and prevention strategies for people living with HIV/AIDS, the HIV pandemic remains a public health crisis in the United States and worldwide, with nearly 40,000 new infections each year in the US alone. To prevent the spread of HIV in vulnerable populations, the US Preventive Services Task Force has recommended HIV pre-exposure pro ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. A Virtual Project-Based Learning Sandbox for Mimetics and Medically Inspired Classroom Engineering (MiMICRE)

    SBC: PARAMETRIC STUDIO, INC.            Topic: 500

    Project Summary/Abstract: The U.S. has more health science STEM jobs available than qualified workers to fill them and lags other OECD nations in math and science, with major achievement gaps and STEM workforce under-representation among women and students of color. Improved STEM education is needed in high school and early collegiate settings that engages, prepares, and inspires all students—an ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. CDK2 inhibitors for protecting hearing loss

    SBC: TING THERAPEUTICS LLC            Topic: NIDCD

    CDK2 inhibitors for protecting hearing loss Ting Therapeutics LLC is a pharmaceutical company developing drugs to prevent and treat hearing loss. Cisplatin is one of the most widely used drugs to treat cancers. However cisplatin anticancer therapy causes high frequency hearing loss in 40-60% of the patients. To date, no drugs have been approved by the Food and Drug Administration for protection fr ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Image-guided dosimetry-based alpha particle therapy for neuroblastoma.

    SBC: VIEWPOINT MOLECULAR TARGETING, INC.            Topic: 105

    SIGNIFICANCE: Neuroblastoma is the most common pediatric cancer, accounting for 15% of cancer deaths, with a 5-yr survival of lt40% due to resistant metastases. Neuroblastoma tumors almost universally express the somatostatin receptor 2 (SSTR2) and high expression has been shown clinically using peptides targeting SSTR2 (PMID10706954). FDA approved SSTR2-targeted beta(β-)-emitting 177Lu-labeled L ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Combining receptor-targeted alpha particle therapy and immunotherapy to achieve complete responses in metastatic melanoma

    SBC: VIEWPOINT MOLECULAR TARGETING, INC.            Topic: NCI

    Revised. Metastatic melanoma is a lethal disease because low response rates (near 50%), acquired resistance, and severe adverse side effects limit long-term quality of life for these patients (5-yr. survival lt30%). Radiopharmaceutical therapies are emerging as an exciting alternative in oncology and systemic receptor- targeted alpha-particle therapy (a-RT) is emerging as particularly transformati ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Preclinical evaluation of an otoprotectant TT002

    SBC: TING THERAPEUTICS LLC            Topic: NIDCD

    Project Summary Ting Therapeutics LLC is a pharmaceutical company developing drugs to prevent and treat hearing loss. Cisplatin is one of the most widely used drugs to treat cancers. However, cisplatin therapy causes hearing loss in 40-60% of the patients. To date, no drugs have been approved by the Food and Drug Administration for protection from cisplatin-induced hearing loss (CIHL). Most candid ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Ultrasound-based diagnostic and monitoring of bladder cancer treatment with drug released from nanoparticles

    SBC: NANOMEDTRIX LLC            Topic: NCI

    Project Summary/Abstract: Transitional cell carcinoma (TCC) of the bladder is the fifth most common form of cancer in the U.S., with over 80,000 new cases expected in 2019. For early-stage carcinomas, patients receive intravesical bacillus Calmette-Guerin (BCG) immunotherapy, or transurethral resection of the bladder tumor (TURBT) with intravesical chemotherapy. Both are associated with a high rat ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  10. ProGel Technology for Better Management of Osteoarthritis Pain

    SBC: ENSIGN PHARMACEUTICAL, INC.            Topic: NIDA

    ABSTRACTAs one of the largest opioid consuming countries in the world, the prevalence of opioid use disorder (OUD) during 2017 is over 5 million in the U.S. alone. The significant increase of opioids use disorder (OUD) cases during the last 2 decades may be partially attributed to our overreliance on the prescription of the opioids for the management of non-cancer chronic pain, such as osteoarthri ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government